Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
Roberto Buonaiuto(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Margherita Tafuro(University of Naples Federico II), Aldo Caltavituro(University of Naples Federico II), Carmine De Angelis(Baylor College of Medicine), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuliana Pavone(University of Catania), Grazia Arpino(University of Naples Federico II), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Alessandra Longobardi(Federico II University Hospital), Martina Pagliuca(Institut Gustave Roussy), P. De Santis(Ospedale Vito Fazzi), Fabio Puglisi(University of Udine)
Cited by 4
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830